Moreover, the adhesion of cells exposed to high dose of ionizing radiation (10 or 15 Gy) to FN is significantly enhanced in the presence of androgen in cells suggesting that integrins play an important role in mediating cell adhesion during radiation therapy. of Vand 1integrins in response to androgen treatment while Bicalutamide abolished this effect. == Conclusions == Our data show that Bicalutamide inhibits the effect of androgen on cell adhesion to FN through changes of integrin subtypes in androgen-dependent prostate cancer cells given high dose radiation. This suggests new PI3K-gamma inhibitor 1 molecular targets and possible treatment strategies for prostate cancer patients to improve the outcome during hormone ablation therapy and radiation therapy. Keywords:LNCaP, Casodex, FN, integrins, extracellular matrix == Introduction == Excluding dermal malignancies, adenocarcinoma (AdCa) of the prostate is now the most common cancer in men and remains the second most lethal malignancy in adult males (1) (2) (3). The transcriptional cascade activated by androgen receptor (AR) plays a key role in prostate function in growth and survival of normal and malignant tissues (4). Methods of early detection have clearly improved tumor identification and stage migration with decreased volume of disease at presentation is now a well-established phenomenon. Although clear progress has been made in the clinical outcomes from patients with low risk clinical features for tumor progression, patients with intermediate and high-risk features remain vulnerable to treatment failure (2)(3)(5)(6). Improved treatment strategies are needed in cases with Gleason scores 7-10 and PSA > 10 patients as these patients appear more vulnerable to treatment failure in spite of optimal treatment planning. Current treatment strategies include surgery, radiation therapy, and hormone ablation therapy in the treatment of patients at the time of disease presentation. External radiation therapy with and without brachytherapy is the local treatment of choice for patients with intermediate and advanced risk of tumor progression (7). Often these patients are treated with hormone intervention used in a neo-adjuvant fashion or concurrent with radiation treatment. This treatment strategy is commonly used in patient care, however when patients fail treatment, they will ultimately fail with androgen-independent/hormone resistant disease (8) (9). One possible strategy to address this problem will be to identify the mechanism of the benefit of hormone therapy and mimic its effect with a targeted therapy, thus keeping hormone therapy as a treatment to use at the time of initial failure (10). This strategy may decrease the rate of failure with androgen-independent disease. Incorporating targeted therapies in a time-sensitive fashion specific to the effects of hormone at presentation may permit hormone to be used at PI3K-gamma inhibitor 1 the time of initial radiation treatment instead of primary or neo-adjuvant therapy. This strategy PI3K-gamma inhibitor 1 may have the potential of delaying the onset of hormone refractory disease that uniformly predicts poor patient outcome. Strategic use of hormone therapy, either fort course or longer treatment, may also influence this effect. Many investigators are also considering using a shorter course of hormone therapy at presentation in patients with high to intermediate risk factors for recurrence to prevent the development of hormone refractory disease. This idea is under careful evaluation for clinical trials at this time. Tumor cell adhesion is an important step in the process of tumor cell growth and metastasis (11). Adhesion promotes interactions between cell-cell and cell-extracellular GNAS matrix (ECM) (12) (13). Integrin expression is up-regulated at low PI3K-gamma inhibitor 1 dose ionizing radiation (14). Inhibiting this process may be important in promoting tumor cell death (15). Our previous study showed this inhibitory effect of high dose radiation therapy on 1integrin expression in prostate cancer cell lines indicating that radiation therapy plays an important role in decreasing cellular PI3K-gamma inhibitor 1 adhesion at high dose ionizing radiation (16). Promoting this effect may be an important aspect of future translational research as treatment directed to this area may.
Moreover, the adhesion of cells exposed to high dose of ionizing radiation (10 or 15 Gy) to FN is significantly enhanced in the presence of androgen in cells suggesting that integrins play an important role in mediating cell adhesion during radiation therapy